SAN DIEGO, Dec. 11, 2025 (GLOBE NEWSWIRE) -- LPL Financial LLC announced today that financial advisor Melissa Mirabile has joined LPL’s employee advisor channel Linsco by LPL Financial to launch Forest Lake Wealth Partners. She reported serving approximately $280 million in advisory, brokerage and retirement plan assets* and joins LPL from UBS. Located in Albany, N.Y., Forest Lake Wealth Partners serves a wide range of clients across the country, including families, business owners, and trade unions. This ...

Core Viewpoint - Epsilon Energy Ltd. has completed the sale of its wholly owned subsidiary, Dewey Energy Holdings, LLC, which includes its Western Anadarko basin assets, to an undisclosed private buyer for $2.5 million in cash [1][2]. Group 1: Transaction Details - The assets sold included approximately 813 Mcfe/d of production, with 60% being natural gas, based on Q3 2025 figures [2]. - The sale encompassed approximately 6,400 net deep acres and 2,200 net shallow acres of leasehold, all located in Dewey County, Oklahoma [2]. - RedOaks Energy Advisors LLC assisted Epsilon in the sell-side process [2]. Group 2: Company Overview - Epsilon Energy Ltd. is a North American onshore natural gas and oil production and gathering company with assets across various basins, including Marcellus, Powder River, Permian, and Western Canadian Sedimentary basins [3].

Fort Lawn, SC, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Northann Corp. (NYSE American: NCL) (the "Company" or "Northann"), today announced it received a notice from the staff of NYSE American LLC (the "Exchange") that the Company was not in compliance with the Exchange's continued listing standards under Section 1003(a)(i) of the NYSE American Company Guide. Section 1003(a)(i) requires a listed company to have stockholders' equity of $2 million or more if the listed company has reported losses from continuing oper ...

WALTHAM, Mass., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced the closing of its previously announced upsized underwritten public offering of 21,827,549 shares of its common stock at a public offering price of $18.44 per share, which includes 2,847,071 shares issued upon the exercise in full by the underwriters of their option to p ...

NEW YORK, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Adamas Trust, Inc. (Nasdaq: ADAM) (the “Company” or “Adamas”) announced today that its Board of Directors (the “Board”) declared a regular quarterly cash dividend of $0.23 per share on shares of its common stock for the quarter ending December 31, 2025. The dividend will be payable on January 28, 2026 to common stockholders of record as of the close of business on December 22, 2025. In addition, the Board declared cash dividends on the Company’s 8.000% Series D Fi ...

SOUTH SAN FRANCISCO, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (NASDAQ: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced it awarded an inducement grant on December 10, 2025 under BBOT’s 2025 Inducement Plan as a material inducement to the employment of an individual hired by BBOT in November 2025. The employee received non-qualified stock options to purchase 53,060 shares of BBOT common stock, par value $0.0 ...

JOHANNESBURG, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Lesaka Technologies, Inc. (NASDAQ: LSAK, JSE: LSK) ("Lesaka") today announced it will release second quarter 2026 results after the U.S. market close on February 4, 2026. Lesaka management will host a presentation webcast and conference call on February 5, 2026, at 8:00am EDT (3:00pm SAST), followed by a live question and answer session for analysts and investors. Webcast Registration Link to access the results webcast: https://www.corpcam.com/Lesaka05022026 P ...

ARR increased 34% year-over-year to $754 millionQ3 revenue increased 33% year-over-year to $184.2 millionSurpassed $1 billion in Remaining Performance Obligations, reflecting 41% year-over-year growthQ3 net cash provided by operating activities was $11.2 million, representing 6% of revenueQ3 free cash flow was $10.6 million, representing a positive 6% free cash flow margin SANTA CLARA, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Netskope (NASDAQ:NTSK) a leader in modern security and networking for the cloud a ...

PHILADELPHIA, Dec. 11, 2025 (GLOBE NEWSWIRE) -- via IBN-- Datavault AI Inc. (NASDAQ: DVLT) (“Datavault AI” or the “Company”), a leader in data monetization, credentialing, and digital engagement technologies, today announced that its board of directors (the “Datavault Board”) has set Dec. 24, 2025, as the distribution date for the Dream Bowl 2026 Meme Coin token (the “Meme Coin”) to all eligible record equityholders of Datavault AI. Dec. 24, 2025, will also be the distribution date for Datavault AI’s volunt ...

Core Insights - Crinetics Pharmaceuticals has initiated the CALM-CAH Phase 3 trial for atumelnant, a novel oral ACTH receptor antagonist aimed at treating classic congenital adrenal hyperplasia (CAH) [1][2] - The trial will assess atumelnant's effectiveness in normalizing adrenal androgen levels and reducing glucocorticoid levels to physiological ranges, setting a new standard for disease control assessment [2][3] - Atumelnant is the first small molecule ACTH receptor antagonist in late-stage clinical development, showing promising results in a Phase 2 study with significant reductions in key biomarkers [2][4] Company Overview - Crinetics Pharmaceuticals focuses on transforming the treatment of endocrine diseases and related tumors, emphasizing patient needs and innovative therapies [5] - The company has a robust pipeline, including its lead product PALSONIFY™ for acromegaly and atumelnant for CAH and ACTH-dependent Cushing's syndrome [6][7] - Crinetics has received Orphan Drug Designation from the FDA for atumelnant, highlighting its potential impact on rare diseases [3]